[go: up one dir, main page]

WO2009031230A1 - 抗ｃｄ２０モノクローナル抗体 - Google Patents

抗ｃｄ２０モノクローナル抗体 Download PDF

Info

Publication number
WO2009031230A1
WO2009031230A1 PCT/JP2007/067444 JP2007067444W WO2009031230A1 WO 2009031230 A1 WO2009031230 A1 WO 2009031230A1 JP 2007067444 W JP2007067444 W JP 2007067444W WO 2009031230 A1 WO2009031230 A1 WO 2009031230A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
monoclonal antibody
monoclonal antibodies
antigen
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/067444
Other languages
English (en)
French (fr)
Inventor
Susumu Uchiyama
Kiichi Fukui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Priority to US12/674,783 priority Critical patent/US20110263825A1/en
Priority to CN200780101422A priority patent/CN101848999A/zh
Priority to PCT/JP2007/067444 priority patent/WO2009031230A1/ja
Priority to JP2009531068A priority patent/JPWO2009031230A1/ja
Priority to EP07806885A priority patent/EP2186892A1/en
Publication of WO2009031230A1 publication Critical patent/WO2009031230A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　ヒトＣＤ２０抗原を発現しているヒトＢ細胞株と、ヒトＣＤ２０のＤＮＡで形質転換された非ヒトかつ被免疫動物とは異なる動物由来の細胞株とを免疫原とするヒトＣＤ２０抗原を有する細胞に対する増殖阻害活性を有するモノクローナル抗体、及びこれをキメラ化又はヒト化したモノクローナル抗体を提供する。本発明のモノクローナル抗体は、医薬として好適な生物学的活性を示す。
PCT/JP2007/067444 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体 Ceased WO2009031230A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/674,783 US20110263825A1 (en) 2007-09-06 2007-09-06 Anti-cd20 monoclonal antibodies
CN200780101422A CN101848999A (zh) 2007-09-06 2007-09-06 抗-cd20单克隆抗体
PCT/JP2007/067444 WO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体
JP2009531068A JPWO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体
EP07806885A EP2186892A1 (en) 2007-09-06 2007-09-06 Anti-cd20 monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/067444 WO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体

Publications (1)

Publication Number Publication Date
WO2009031230A1 true WO2009031230A1 (ja) 2009-03-12

Family

ID=40428553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/067444 Ceased WO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体

Country Status (5)

Country Link
US (1) US20110263825A1 (ja)
EP (1) EP2186892A1 (ja)
JP (1) JPWO2009031230A1 (ja)
CN (1) CN101848999A (ja)
WO (1) WO2009031230A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113308A1 (zh) 2010-03-17 2011-09-22 永卓博济(上海)生物医药技术有限公司 一种新型人源化抗cd20单克隆抗体
JP2016512489A (ja) * 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551050A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
IL312059A (en) 2018-11-19 2024-06-01 Biora Therapeutics Inc Methods and devices for treating a disease with biotherapeutics
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502408A (ja) * 1988-12-28 1992-05-07 プロテイン　デザイン　ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502408A (ja) * 1988-12-28 1992-05-07 プロテイン　デザイン　ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONG K. ET AL.: "Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD 20.", J.IMMUNOL. METHODS., vol. 294, no. 1-2, 2004, pages 189 - 197, XP004679767 *
PRESTA LG. ET AL.: "Humanization of an anti- vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.", CANCER RES., vol. 57, no. 20, 1997, pages 4593 - 4599, XP055354366 *
YOSHIYA TANAKA: "Ko CD 20 Kotai", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 63, no. 5, 2005, pages 728 - 733, XP008132095 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113308A1 (zh) 2010-03-17 2011-09-22 永卓博济(上海)生物医药技术有限公司 一种新型人源化抗cd20单克隆抗体
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US10344096B2 (en) 2012-08-24 2019-07-09 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US11312787B2 (en) 2012-08-24 2022-04-26 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US12162950B2 (en) 2012-08-24 2024-12-10 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
JP2016512489A (ja) * 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3636660A1 (en) 2015-05-30 2020-04-15 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3660035A1 (en) 2015-05-30 2020-06-03 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
US11654193B2 (en) 2016-06-27 2023-05-23 The Regents Of The University Of California Cancer treatment combinations

Also Published As

Publication number Publication date
EP2186892A1 (en) 2010-05-19
US20110263825A1 (en) 2011-10-27
CN101848999A (zh) 2010-09-29
JPWO2009031230A1 (ja) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2009031230A1 (ja) 抗ｃｄ２０モノクローナル抗体
WO2011050106A3 (en) Anti-cd3 antibody dosing in autoimmune disease
WO2011062997A3 (en) Human monoclonal antibodies to human nucleolin
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2005103081A3 (en) Human monoclonal antibodies against cd20
UA101487C2 (en) Humanized b-ly1 antibody formulation
WO2019089969A3 (en) Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EP2143795A3 (en) Anti-CD20 monoclonal antibody
WO2006117699A3 (en) Transgenic animals and methods of making recombinant antibodies
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
WO2006089231A3 (en) Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
EP3539988A3 (en) Monoclonal antibodies against her2
WO2011069019A3 (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
WO2010102276A3 (en) Humanized anti-cd19 antibody formulations
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
IL184733A0 (en) Human monoclonal antibodies to prostate specific membrane
BRPI0606547A2 (pt) anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
NZ600262A (en) Anti-her3 antibodies and uses thereof
WO2008069999A3 (en) Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780101422.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07806885

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12674783

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007806885

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009531068

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE